101
|
Aguirre AR, Abensur H. Protective measures against ultrafiltration failure in peritoneal dialysis patients. Clinics (Sao Paulo) 2011; 66:2151-7. [PMID: 22189743 PMCID: PMC3226613 DOI: 10.1590/s1807-59322011001200023] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2011] [Accepted: 08/18/2011] [Indexed: 01/17/2023] Open
Abstract
Ultrafiltration failure in patients undergoing peritoneal dialysis is a condition with an incidence that increases over time. It is related to increased cardiovascular morbidity and mortality and is a major cause of the abandonment of the treatment technique. Because the number of patients undergoing renal replacement therapy is increasing with society aging and because approximately 10% of this population is treated with peritoneal dialysis, this matter is becoming more common in everyday practice for clinicians involved in the care of patients with chronic renal failure. In this review, we summarize the available measures used to prevent and treat ultrafiltration failure and the current state of research in the field, both in the experimental and clinical settings, focusing on the possible clinical applications of recent findings.
Collapse
Affiliation(s)
- Anna Rita Aguirre
- Hospital das Clínicas, Universidade de São Paulo, Nephrology Division, São Paulo, SP, Brazil.
| | | |
Collapse
|
102
|
Davenport A, Sayed RH, Fan S. Is Extracellular Volume Expansion of Peritoneal Dialysis Patients Associated with Greater Urine Output? Blood Purif 2011; 32:226-31. [DOI: 10.1159/000329732] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2011] [Accepted: 05/22/2011] [Indexed: 11/19/2022]
|
103
|
Woodrow G, Davies S. Renal Association Clinical Practice Guideline on Peritoneal Dialysis. ACTA ACUST UNITED AC 2011; 118 Suppl 1:c287-310. [DOI: 10.1159/000328073] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2010] [Accepted: 08/06/2010] [Indexed: 11/19/2022]
|
104
|
Qi H, Xu C, Yan H, Ma J. Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: a meta-analysis of randomized controlled trials. Perit Dial Int 2010; 31:179-88. [PMID: 21119069 DOI: 10.3747/pdi.2009.00264] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND Icodextrin is widely used in peritoneal dialysis (PD); however, the safety and efficacy of icodextrin are unclear. In the present study, we performed a systematic review of randomized controlled trials (RCTs) that compared icodextrin and glucose for the once-daily long dwell in PD. METHODS Electronic searches were performed in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials to select all eligible studies. Eligible studies, as determined by consensus using predefined criteria, were reviewed, and data were extracted onto a standard form. RESULTS In the 9 RCTs that were identified, patients using icodextrin were found to have much greater net ultrafiltration (UF) and a lower incidence of negative net UF compared to patients using 1.5%, 2.5%, and 4.25% glucose solutions. Additionally, icodextrin has a markedly increased UF efficiency ratio and peritoneal clearance of creatinine and urea nitrogen, but residual renal function was not different from patients using glucose solutions for PD. No significant differences were observed between icodextrin and glucose groups with respect to risk of mortality, peritonitis, and total adverse events. Although rashes occurred significantly more often in icodextrin groups, few differences were noted between icodextrin and glucose groups when withdrawal rates secondary to adverse events were compared. CONCLUSIONS This meta-analysis suggests that icodextrin provides patients with greater fluid removal and small solute clearance and does not cause any damage to residual renal function. Icodextrin is particularly appropriate for use in patients with high peritoneal transport status.
Collapse
Affiliation(s)
- Hualin Qi
- Department of Nephrology, East Hospital, Tongji University School of Medicine, Shanghai, China
| | | | | | | |
Collapse
|
105
|
Kay Tan B, Chan C, Davies SJ. Achieving Euvolemia in Peritoneal Dialysis Patients: A Surprisingly Difficult Proposition. Semin Dial 2010; 23:456-61. [DOI: 10.1111/j.1525-139x.2010.00739.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
106
|
John B, Tan BK, Dainty S, Spanel P, Smith D, Davies SJ. Plasma volume, albumin, and fluid status in peritoneal dialysis patients. Clin J Am Soc Nephrol 2010; 5:1463-70. [PMID: 20538836 DOI: 10.2215/cjn.09411209] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND AND OBJECTIVES Peritoneal dialysis (PD) patients may be overhydrated especially when inflammation is present. We hypothesized that patients with a plasma albumin below the median value would have measurable overhydration without a proportional increase in plasma volume (PV). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS We investigated a cross-sectional sample of 46 prevalent PD patients powered to detect a proportional increase in PV associated with whole body overhydration and hypoalbuminemia. PV was determined from (125)I-labeled albumin dilution, absolute total body water from D dilution (TBW(D)), and relative hydration from multifrequency bioimpedance analysis (BIA; Xitron 4200) expressed as the extracellular water (ECW):TBW(BIA) ratio. RESULTS Whereas patients with plasma albumin below the median (31.4 g/dl) were overhydrated as determined both by BIA alone (ECW:TBW(BIA) 0.49 versus 0.47, P < 0.036) and the difference between estimated TBW(BIA) and measured TBW(D) (3.55 versus 0.94 L, P = 0.012), corrected PV was not different (1463 versus 1482 ml/m(2), NS). Mean PV was not different from predicted, and its variance did not correlate with any other clinical measures. Multivariate analysis showed that the only independent predictor of whole body overhydration was reduced plasma albumin. CONCLUSIONS Hypoalbuminemia is an important determinant of tissue overhydration in PD patients. This overhydration is not associated with an increased plasma volume. Attempts to normalize the ECW:TBW ratio in hypoalbuminemic, inflamed PD patients may lead to hypovolemia and loss of residual renal function.
Collapse
Affiliation(s)
- Biju John
- Department of Nephrology, University Hospital of North Staffordshire, Stoke on Trent, Staffordshire, United Kingdom
| | | | | | | | | | | |
Collapse
|
107
|
|
108
|
Chaudhary K, Khanna R. Biocompatible Peritoneal Dialysis Solutions: Do We Have One?: Table 1. Clin J Am Soc Nephrol 2010; 5:723-32. [DOI: 10.2215/cjn.05720809] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
109
|
Devolder I, Verleysen A, Vijt D, Vanholder R, Van Biesen W. Body composition, hydration, and related parameters in hemodialysis versus peritoneal dialysis patients. Perit Dial Int 2010; 30:208-14. [PMID: 20081049 DOI: 10.3747/pdi.2008.00284] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
AIMS Maintaining euvolemia is an important goal in patients on renal replacement therapy. However, adequate assessment of volume status in clinical practice is hampered by a lack of accurate measuring tools. A new multifrequency bioimpedance tool has recently been validated. This study compares volume status in peritoneal dialysis (PD) and hemodialysis (HD) patients in a single center. METHODS Body Composition Monitoring (BCM; Fresenius Medical Care, Bad Homburg, Germany) was performed in all patients on PD or HD without contraindication. PD patients were measured with a full abdomen; HD patients were measured at the midweek session, once immediately before and once 20 minutes after dialysis. Clinical overhydration was defined as an overhydration-to-extracellular water ratio of >0.15. RESULTS Total body water, extracellular water, and intracellular water were 33.7 +/- 6.9 L versus 31.8 +/- 8.1 L vs 33.9 +/- 6.7 L, 16.4 +/- 3.9 L vs 15.3 +/- 4.9 L vs 16.8 +/- 3.3 L, and 17.1 +/- 6.2 L vs 16.5 +/- 4.6 L vs 17.2 +/- 3.9 L in the pre-HD, post-HD, and PD patients, respectively (p = NS). In the pre-HD and the PD patients, overhydration was 1.9 +/- 1.7 L and 2.1 +/- 2.3 L, whereas post-HD this was only 0.6 +/- 1.7 L (p < 0.001). Clinical overhydration was more prevalent in pre-HD and PD patients compared to post-HD patients (24.1% vs 22.3% vs 10%, p < 0.001). In multivariate models, overhydration was related to age, male gender, and post-HD status. CONCLUSION Although much clinical attention is paid to volume status, 24% of patients still have clinically relevant volume overload. Implementation of a reliable and clinically applicable tool to assess volume status is therefore necessary. It is possible to obtain comparable volume status in PD and HD patients.
Collapse
|
110
|
Kramer A, Stel V, Zoccali C, Heaf J, Ansell D, Grönhagen-Riska C, Leivestad T, Simpson K, Pálsson R, Postorino M, Jager K. An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant 2009; 24:3557-66. [PMID: 19820003 DOI: 10.1093/ndt/gfp519] [Citation(s) in RCA: 100] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Recent studies have indicated a stabilization in the incidence rates of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in a number of European countries. The aim of this study was to provide an update on the incidence, prevalence and outcomes of RRT in Europe over the past decade. METHODS Nineteen European national or regional renal registries with registry data from 1997 to 2006 participated in the study. Incidence and prevalence trends were analysed with Poisson and Joinpoint regression. Cox regression methods were used to examine patient survival. RESULTS The total adjusted incidence rate of RRT for ESRD increased from 109.9 per million population (pmp) in 1997 to 119.7 pmp in 2000, i.e. an average annual percentage change (AAPC) of 2.9% (95% CI 2.1-3.8%). Thereafter, the incidence increased at a much lower rate to 125.4 pmp in 2006 [AAPC 0.6% (95% CI 0.3-0.8%)]. This change in the trend of the incidence of RRT was largely due to a stabilization in the incidence rates of RRT for females aged 65-74 years, males aged 75-84 years and patients receiving RRT for ESRD due to hypertension/renal vascular disease. The overall adjusted prevalence in Europe continued to increase linearly at 2.7% per year. Between the periods 1997-2001 and 2002-2006, the risk of death decreased for all treatment modalities, with the most substantial improvement in patients starting peritoneal dialysis [19% (95% CI 15-22%)] and in patients receiving a kidney transplant [17% (95% CI 11-23%)]. CONCLUSION This European study shows that the annual rise of the overall incidence rate of RRT for ESRD has diminished and that in several age groups the incidence rates have now stabilized. The survival of dialysis patients and kidney transplant recipients has continued to improve.
Collapse
Affiliation(s)
- Anneke Kramer
- ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
111
|
Nakayama M, Kasai K, Imai H. Novel Low Na Peritoneal Dialysis Solutions Designed to Optimize Na Gap of Effluent: Kinetics of Na and Water Removal. Perit Dial Int 2009. [DOI: 10.1177/089686080902900510] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Background An imbalance between sodium intake to and excretion from the body contributes to overhydration in peritoneal dialysis (PD) patients. Novel low Na solutions were developed based on the concept of optimizing the Na gap of effluent to achieve better Na balance. The present study investigated Na and water removal by those solutions. Methods Compositions of low Na (LS) and standard Na (SS) solutions were as follows: Na 133, 126, and 118 mEq/L with respective corresponding glucose concentrations of 0.9%, 1.6%, and 2.5% in LS(90), LS(160), and LS(250) solutions; Na 135 mEq/L with glucose 1.35% and 2.5% in SS(135) and SS(250) solutions respectively. Based on the status of their daily PD prescriptions, respective LS solutions were assigned to 41 patients as follows: LS(90) or LS(160) for SS(135) solution, and LS(160) or LS(250) for SS(250) solution. Results In the 4-hour dwell, no differences were found in Na removal between LS(90) and SS(135), whereas Na removal by LS(160) and LS(250) was significantly increased compared to SS(135) and SS(250) ( p < 0.05 respectively). The Na gaps of the 3 respective LS solutions were significantly less than those of controls ( p < 0.05 respectively). With 1-day full-time use of LS solutions, no significant changes were found in daily water removal compared to controls, while Na removal was significantly increased in LS solutions ( p < 0.05), with conversion to a negative Na gap in total daily effluent. Conclusion The low Na solutions used in the present study facilitated Na removal by reducing the Na gap. This characteristic is expected to achieve better Na balance in PD patients with excess body fluid retention.
Collapse
Affiliation(s)
- Masaaki Nakayama
- Research of Division of Dialysis and Chronic Kidney Disease, Tohoku University Graduate School of Medicine, Sendai
| | - Kenji Kasai
- Department of Nephrology, Fuji City General Hospital, Shizuoka
| | - Hirokazu Imai
- Division of Nephrology and Rheumatology, Department of Internal Medicine, Aichi Medical University School of Medicine, Aichi, Japan
| |
Collapse
|
112
|
Lin W, Chen YC, Wu MS, Hsu HJ, Sun CY, Lin YK, Wu IW. Icodextrin Dialysate Improves Nutritional and Inflammatory Profiles in Peritoneal Dialysis Patients. Ren Fail 2009; 31:98-105. [DOI: 10.1080/08860220802595500] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
113
|
Freida P, Issad B, Dratwa M, Lobbedez T, Wu L, Leypoldt JK, Divino-Filho JC. A Combined Crystalloid and Colloid PD Solution as a Glucose-Sparing Strategy for Volume Control in High-Transport APD Patients: A Prospective Multicenter Study. Perit Dial Int 2009. [DOI: 10.1177/089686080902900410] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Background Evidence is accumulating that the continuous exposure to high glucose concentrations during peritoneal dialysis (PD) is an important cause of ultrafiltration (UF) failure. The cornerstone of prevention and treatment of UF failure is reduction of glucose exposure, which will also alleviate the systemic impact of significant free glucose absorption. The challenge for the future is to discover new therapeutic strategies to enhance fluid and sodium removal while diminishing glucose load and exposure using combinations of available osmotic agents. Objectives To investigate in patients on automated PD (APD) with a fast transport pattern whether there is a glucose-sparing advantage to replacing 7.5% icodextrin (ICO) during the long dwell with a mixed crystalloid and colloid PD fluid (bimodal UF) in an attempt to promote daytime UF and sodium removal while diminishing the glucose strength of the dialysate at night. Design A 2 parallel arm, 4 month, prospective nonrandomized study. Setting PD units or university hospitals in 4 French and Belgian districts. Results During the 4-month intervention period, net UF and peritoneal sodium removal during the long dwell when treated by bimodal UF was about 2-fold higher than baseline (with ICO). The estimated percent change (95% confidence interval) from baseline in net daytime UF for the bimodal solution was 150% (106% – 193%), versus 18% (–7% – 43%) for ICO ( p < 0.001). The estimated percent change from baseline in peritoneal sodium removal for the bimodal solution was 147% (112% – 183%), versus 23% (–2% – 48%) for ICO ( p < 0.001). The estimated percent change from baseline in UF efficiency (24-hour net UF divided by the amount of glucose absorbed) was significantly higher ( p < 0.001) when using the bimodal solution was 71%, versus -5% for ICO. Conclusion Prescription of bimodal UF during the day in APD patients offers the opportunity to optimize the long dwell exchange in a complete 24-hour APD cycle. The current study demonstrated that a bimodal solution based on the mixing of glucose (2.6%) and icodextrin (6.8%) achieved the double target of significantly improving UF and peritoneal sodium removal by exploring a new concept of glucose-sparing PD therapy.
Collapse
Affiliation(s)
- Philippe Freida
- Department of Clinical Nephrology and Dialysis, CHPC Hôpital Louis Pasteur, Cherbourg
| | - Belkacem Issad
- Peritoneal Dialysis Unit, La Pitié–Salpétrière University Hospital, Paris, France
| | - Max Dratwa
- Department of Nephrology and Dialysis, Brugmann University Hospital, Brussels, Belgium
| | - Thierry Lobbedez
- Department of Nephrology and Dialysis, CHR Clemenceau, Caen, France
| | - LieLing Wu
- Statistics, Epidemiology and Surveillance, Baxter Healthcare Corporation, Round Lake
| | - John K. Leypoldt
- Renal Division, Baxter Healthcare Corporation, McGaw Park, Illinois, USA
| | - Jose Carolino Divino-Filho
- Divisions of Baxter Novum and Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
- Baxter Renal Division Latin America, Mexico City, Mexico
| |
Collapse
|
114
|
|
115
|
Lambie M, Stompor T, Davies S. Understanding the variability in Ultrafiltration Obtained with Icodextrin. Perit Dial Int 2009. [DOI: 10.1177/089686080902900406] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Mark Lambie
- University Hospital of North Staffordshire
- Institute for Science and Technology in Medicine Keele University, Stoke-on-Trent, UK
| | - Tomasz Stompor
- Department of Nephrology Jagiellonian University, Kraków, Poland
| | - Simon Davies
- University Hospital of North Staffordshire
- Institute for Science and Technology in Medicine Keele University, Stoke-on-Trent, UK
| |
Collapse
|
116
|
Sav T, Oymak O, Inanc MT, Dogan A, Tokgoz B, Utas C. Effects of Twice-Daily Icodextrin Administration on Blood Pressure and Left Ventricular Mass in Patients on Continuous Ambulatory Peritoneal Dialysis. Perit Dial Int 2009. [DOI: 10.1177/089686080902900411] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Background Hypervolemia is a risk factor for left ventricular hypertrophy and hypertension in peritoneal dialysis patients. Icodextrin improves volume control by increasing ultrafiltration in peritoneal dialysis patients. Aim To examine the effects of twice-daily icodextrin administration on blood pressure and left ventricular hypertrophy in peritoneal dialysis patients with hypervolemia and ultrafiltration failure. Method and Results Administration of icodextrin twice daily resulted in a significant reduction in the left ventricular mass index (LVMI) of patients by the end of the third month ( p < 0.05). The reduction in LVMI was also significant for the once-daily icodextrin group ( p < 0.05). Mean blood pressure of patients receiving icodextrin twice daily was significantly reduced ( p < 0.05). By the end of the third month no significant changes were observed in mean blood pressure of the patients using once-daily icodextrin ( p > 0.05). No statistically significant changes were observed in weekly total creatinine clearances or Kt/V of patients in either group at the end of 3 months (NS). Conclusion Twice-daily icodextrin administration was clinically beneficial as shown by reduced blood pressure and prevention of the progress of left ventricular hypertrophy without causing any decrease in dialysis adequacy or any side effects. The icodextrin metabolite results did not suggest any further increase in their values when comparing once- to twice-daily administration of icodextrin. Although prescription of icodextrin once daily may yield good clinical results in the long term, this study showed that it may be more efficient to use twice-daily icodextrin for at least a specific period for the purpose of obtaining quicker results in patients with ultrafiltration failure, serious hypervolemia, or hard-to-control blood pressure conditions.
Collapse
Affiliation(s)
- Tansu Sav
- Department of Nephrology, Government Hospital
| | - Oktay Oymak
- Department of Nephrology, Erciyes University, Kayseri, Turkey
| | | | - Ali Dogan
- Department of Cardiology, Erciyes University, Kayseri, Turkey
| | - Bulent Tokgoz
- Department of Nephrology, Erciyes University, Kayseri, Turkey
| | - Cengiz Utas
- Department of Nephrology, Erciyes University, Kayseri, Turkey
| |
Collapse
|
117
|
Davies SJ. Preserving residual renal function in peritoneal dialysis: volume or biocompatibility? Nephrol Dial Transplant 2009; 24:2620-2. [DOI: 10.1093/ndt/gfp313] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
118
|
Perl J, Bargman JM. The Importance of Residual Kidney Function for Patients on Dialysis: A Critical Review. Am J Kidney Dis 2009; 53:1068-81. [PMID: 19394737 DOI: 10.1053/j.ajkd.2009.02.012] [Citation(s) in RCA: 122] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2008] [Accepted: 02/06/2009] [Indexed: 11/11/2022]
|
119
|
Kim S, Oh J, Kim S, Chung W, Ahn C, Kim SG, Oh KH. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24:2899-908. [PMID: 19258384 DOI: 10.1093/ndt/gfp054] [Citation(s) in RCA: 89] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND In vitro studies of peritoneal dialysis (PD) solutions demonstrated that a biocompatible fluid with neutral-pH and low glucose degradation products (LF) has better biocompatibility than a conventional acidic lactate-buffered fluid (CF). However, few clinical trials have investigated the effects of the biocompatible solution on residual renal function (RRF). We performed a prospective, randomized trial with patients starting continuous ambulatory peritoneal dialysis (CAPD). METHODS Ninety-one incident patients started CAPD for 12-month treatment with either LF (Balance, Fresenius, n = 48) or CF (CAPD/DPCA, Fresenius, n = 43). RRF, peritoneal solute transport rate and solute clearance were measured every 6 months. RESULTS LF had a significant effect on the change of glomerular filtration rate (GFR) (P = 0.048 by the mixed model). In per-protocol analysis, GFR in the LF group did not decrease over a 12-month period, while GFR in the control group significantly decreased (0.13 +/- 33.4 L/ week/1.73 m(2) for LF versus -13.6 +/- 19.4 L/week/1.73 m(2) for CF, P = 0.049). Subgroup analysis for patients with initial GFR of 2 mL/min/1.73 m(2) or above showed a significantly higher GFR for the LF group over the 12-month period. At Month 13, serum total CO(2) levels were higher and serum albumin levels were lower in the LF group. No differences between the two groups were observed for the C-reactive protein. Over the 12-month period, effluent cancer antigen-125 levels significantly increased in the LF group, compared with those of the CF group, while effluent interleukin-6 levels were not different between the two groups. CONCLUSION Our study suggests that LF may better preserve RRF over the 12-month treatment period in incident CAPD patients.
Collapse
Affiliation(s)
- Sejoong Kim
- Department of Internal Medicine, Gachon University of Medicine and Science, Incheon, Korea
| | | | | | | | | | | | | |
Collapse
|
120
|
Cueto–Manzano AM. Rapid Solute Transport in the Peritoneum: Physiologic and Clinical Consequences. Perit Dial Int 2009. [DOI: 10.1177/089686080902902s17] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
This review focuses on the physiologic and clinical consequences of rapid solute transport in the peritoneum. The concept, the current understanding of related factors, and the possible causes implicated in rapid solute transport are discussed first. Then, the consequences, with particular emphasis on mortality, are highlighted. Finally, based on recent advances and clinical studies, some strategies for the treatment of fast peritoneal transport are reviewed.
Collapse
Affiliation(s)
- Alfonso M. Cueto–Manzano
- Unidad de Investigatión Médica en Enfermedades Renales, UMAE Hospital de Especialidades, CMNO, IMSS, Guadalajara, Mexico
| |
Collapse
|
121
|
van den Berg R, Cnossen TT, Konings CJAM, Kooman JP, van der Sande FM, Leunissen KML. Different treatment options in peritoneal dialysis. NDT Plus 2008; 1:iv14-iv17. [PMID: 25983979 PMCID: PMC4421140 DOI: 10.1093/ndtplus/sfn118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2008] [Accepted: 06/19/2008] [Indexed: 11/24/2022] Open
Abstract
Patients with end-stage renal disease (ESRD) are placed on dialysis while they await kidney transplantation. The mortality rate among patients with ESRD is high. This review outlines the importance of preservation of residual renal function (RRF) and supports the idea of the integrated care approach to uraemia where patients start on peritoneal dialysis (PD).
Collapse
Affiliation(s)
- Roy van den Berg
- Department of Internal Medicine, St Catharina Hospital Eindhoven
| | | | | | - Jeroen P. Kooman
- Division of Nephrology, University Hospital Maastricht, The Netherlands
| | | | | |
Collapse
|
122
|
Sood MM, Pauly RP, Rigatto C, Komenda P. Left ventricular dysfunction in the haemodialysis population. NDT Plus 2008; 1:199-205. [PMID: 25983883 PMCID: PMC4421219 DOI: 10.1093/ndtplus/sfn074] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2008] [Accepted: 05/29/2008] [Indexed: 11/14/2022] Open
Abstract
Cardiovascular disease in the haemodialysis population continues to contribute to mortality and morbidity. Disorders of left ventricular geometry and function are highly prevalent and lead to increased mortality in this highly vulnerable population. Left ventricular dysfunction (LVDys), often as a result of hypertension, ischaemic cardiac disease or dilated cardiomyopathy, has not been uniformly defined in the literature making diagnosis and therapy problematic. Although routinely available, screening by echocardiography is critically volume dependent and prone to underestimation in left ventricular ejection fraction. Few randomized control trials are available to guide management with the majority of evidence requiring extrapolation from the non-dialysis population. Beyond medication, interventional cardiac procedures such as implantable cardiac defibrillator implantation and cardiac resynchronization therapy show promise. Conversion to alternative dialysis modalities such as peritoneal dialysis, short-daily or nocturnal dialysis have been attempted and are actively being explored.
Collapse
Affiliation(s)
- Manish M. Sood
- St Boniface General Hospital and the University of Manitoba, Winnipeg, Manitoba, Canada
| | - Robert P. Pauly
- Edmonton General Hospital, University of Alberta, Edmonton, Alberta, Canada
| | - Claudio Rigatto
- St Boniface General Hospital and the University of Manitoba, Winnipeg, Manitoba, Canada
| | - Paul Komenda
- St Boniface General Hospital and the University of Manitoba, Winnipeg, Manitoba, Canada
| |
Collapse
|
123
|
Davies SJ, Lopez EG, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimburger O, Simonsen O, Davenport A, Lindholm B, Tranaeus A, Filho JCD. Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange. Nephrol Dial Transplant 2008; 23:2982-8. [DOI: 10.1093/ndt/gfn176] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
124
|
Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis. Kidney Int 2008:S125-30. [DOI: 10.1038/sj.ki.5002613] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
125
|
Abstract
Peritoneal dialysis is now utilized as a renal replacement therapy modality in a substantial percentage of patients with end-stage renal disease, with excellent short-term patient and technique survival rates. However, the potential complications associated with longer-term therapy, such as ultrafiltration failure or encapsulating peritoneal sclerosis, have led to raise some concern about peritoneal dialysis as an adequate mode of treatment of end-stage renal disease in the long term. In the last decade, a substantial amount of information has been gathered on the characteristics of the peritoneal membrane at the onset of peritoneal dialysis, and on the anatomical and pathophysiologic changes that occur with long-term peritoneal dialysis. I will review this subject with a special focus on the various strategies that can help protect the peritoneal membrane during peritoneal dialysis so as to allow peritoneal dialysis to succeed as a long-term dialysis modality.
Collapse
Affiliation(s)
- Eric Goffin
- Department of Nephrology, Université Catholique de Louvain, Brussels, Belgium.
| |
Collapse
|
126
|
The new peritoneal dialysis solutions: friends only, or foes in part? ACTA ACUST UNITED AC 2007; 3:604-12. [DOI: 10.1038/ncpneph0620] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2007] [Accepted: 06/29/2007] [Indexed: 11/08/2022]
|
127
|
Krediet RT. Opinion: What Are the Problems with Using the Peritoneal Membrane for Long-Term Dialysis? Semin Dial 2007. [DOI: 10.1111/j.1525-139x.2007.00385_2.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
128
|
Chung SH, Heimbürger O, Lindholm B. Editorial: Poor Outcomes for Fast Transporters on PD: The Rise and Fall of a Clinical Concern. Semin Dial 2007; 21:7-10. [DOI: 10.1111/j.1525-139x.2007.00327.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
129
|
Abstract
Membrane function at the start of peritoneal dialysis (PD) treatment, measured as solute transport rate and ultrafiltration capacity, varies considerably between individuals. Although this can be correlated to clinical factors such as age and body habitus, this accounts for little of the variance seen. It is increasingly clear, however, that this variability in membrane function does impact on clinical outcomes. Specifically, high solute transport increases mortality risk, independent of other known factors such as age, comorbidity, and residual renal function. High solute transport causes earlier loss of the osmotic gradient when a low molecular weight osmolyte such as glucose is used. This will result in an earlier and lower peak in the ultrafiltration achieved combined with a higher fluid absorption rate once the osmotic gradient is lost. It is therefore quite plausible that the worse clinical outcomes associated with high transport reflect less good ultrafiltration, although other explanations must be considered, including higher peritoneal protein losses and a possible association with systemic inflammation. Strategies now exist to mitigate the effects of high transport on fluid removal. These include optimization of the short dwell lengths using automated PD (APD) combined with icodextrin which will result in sustained ultrafiltration and thus prevention of reabsorption in the long dwell. Survival analysis of APD patients, especially in cohorts in which icodextrin has been used, would suggest that high transport status is not a risk factor, although some of these data are only preliminary. In contrast, low ultrafiltration capacity of the membrane seems to be more important in these patients, especially if anuric. Here the best strategy would seem to be prevention as patients who develop low ultrafiltration capacity are not easily treated on PD. Avoiding excessive hypertonic glucose exposure and preserving residual renal function offers the best available approach.
Collapse
Affiliation(s)
- S J Davies
- Institute for Science and Technology in Medicine, Keele University, Keele, UK.
| |
Collapse
|
130
|
Pérez-Fontán M, Rodríguez-Carmona A. Comparing Capd and Automated Peritoneal Dialysis: Where do Solute Transport Issues Stand? Perit Dial Int 2007. [DOI: 10.1177/089686080702700212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
131
|
Tang W, Cheng LT, Wang T. Diabetic patients can do as well on peritoneal dialysis as nondiabetic patients. Blood Purif 2005; 23:330-7. [PMID: 16118488 DOI: 10.1159/000087771] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/11/2005] [Indexed: 11/19/2022]
Abstract
BACKGROUND It is not uncommon that diabetic peritoneal dialysis (PD) patients are volume overloaded and this may have contributed to the inferior outcome of diabetic patients. In the present cohort study, we compared the difference between diabetics and nondiabetics during the first year of PD after implementing strict volume control. METHODS Seventeen diabetic and 40 nondiabetic incident PD patients were followed for 1 year. Fluid status was evaluated by bioimpedance analysis and blood pressure. Nutritional status was evaluated by subjective global nutritional assessment. RESULTS At the initiation, compared with the nondiabetics, diabetics had a significantly higher extracelluar volume, systolic blood pressure and lower serum albumin. One year later, there were no statistical differences in these parameters between the two groups. The prevalence of malnutrition decreased in all patients, although malnutrition remained slightly higher in diabetic patients. CONCLUSIONS Our study suggests that diabetics can do as well as nondiabetics on PD. Appropriate diabetic care, especially strict volume control, may be critical for the success of diabetic patients on PD treatment.
Collapse
Affiliation(s)
- Wen Tang
- Institute of Nephrology, First Hospital, Peking University, Beijing, China
| | | | | |
Collapse
|
132
|
Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2005; 66:2437-45. [PMID: 15569337 DOI: 10.1111/j.1523-1755.2004.66021.x] [Citation(s) in RCA: 154] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
BACKGROUND Time on treatment is associated with a greater risk of impaired ultrafiltration (UF) in peritoneal dialysis (PD) patients. In addition to increasing solute transport, a potentially treatable cause of impaired ultrafiltration, cross-sectional studies suggest that there is also reduced osmotic conductance of the membrane. If this were the case then it would be expected that the UF capacity for a given rate of solute transport would change with time. The purpose of this analysis was to establish how solute transport and UF capacity change relative to one another with time on therapy. METHODS Membrane function, using a standard peritoneal equilibration test, was measured at least annually in a well-characterized, single-center observational cohort of PD patients between 1990 and 2003. Demography included age, gender, original cause of renal failure, body surface area (BSA), validated comorbidity score, residual urine volume and urea clearances, peritoneal urea clearances, and plasma albumin. RESULTS Data from 574 new PD patients were available for analysis. Independent demographic factors associated with higher solute transport at baseline were male gender and higher residual urine volume. Throughout time on therapy there was a negative relationship between solute transport and UF capacity and a significant increase and decrease in these parameters, respectively. During the first 12 months of treatment, the increase in solute transport was not associated with the expected fall in UF capacity, a phenomenon that was not explained by informative censoring, but was associated with an increased, albeit weak, correlation with BSA. In contrast, later in treatment there was a disproportionate fall in UF capacity, more accelerated in patients developing UF failure. Early exposure to higher intraperitoneal glucose concentrations, in the context of more comorbidity and relative lack of residual renal function, was associated with more rapid deterioration in membrane function. CONCLUSION Despite a causal link between solute transport and UF capacity of the membrane, due to the effect of the former on the osmotic gradient, there is evidence of their longitudinal dissociation. This implies a change in the structure-function relationship with time on treatment that can, to some extent, be predicted from clinical factors present within the first year of treatment. Dialysis-induced membrane injury must involve at least two processes, for example, increased vascular surface area contact with dialysate combined with changes in hydraulic conductance due to scarring of the vessels and interstitium.
Collapse
Affiliation(s)
- Simon J Davies
- Department of Nephrology, University Hospital of North Staffordshire, Stoke-on-Trent, Staffordshire, United Kingdom.
| |
Collapse
|
133
|
Abstract
PURPOSE OF REVIEW Acute renal failure (ARF) is a syndrome that occurs when there is a sudden decline in the glomerular filtration rate. The purpose of this review is to examine new developments and clinical applications of renal replacement therapies including hemodialysis, continuous renal replacement therapy, the bioartificial kidney, and peritoneal dialysis in the management of this complicated syndrome. RECENT FINDINGS New developments in hemodialysis include in-line hematocrit monitoring and improved biocompatible dialyzer membranes. While recent studies indicate that increased delivery of dialysis improves the outcome of patients with ARF, the optimal regimen of intermittent dialysis or continuous renal replacement therapy remains to be determined. The bioartificial kidney, combining hemofiltration with a device containing human tubular cells, is currently in clinical trials and represents another alternative in the management of ARF. In peritoneal dialysis, new solutions using icodextrin may improve fluid removal and blood pressure. SUMMARY The optimal choice of renal replacement therapy depends on many factors. Use of new options in renal replacement therapy and early initiation of dialysis may help to improve survival and outcome of patients with ARF.
Collapse
Affiliation(s)
- Albert Quan
- Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
| | | |
Collapse
|
134
|
Beerenhout CH, Luik AJ, Jeuken-Mertens SGJ, Bekers O, Menheere P, Hover L, Klaassen L, van der Sande FM, Cheriex EC, Meert N, Leunissen KM, Kooman JP. Pre-dilution on-line haemofiltration vs low-flux haemodialysis: a randomized prospective study. Nephrol Dial Transplant 2005; 20:1155-63. [PMID: 15784639 DOI: 10.1093/ndt/gfh775] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Accumulation of larger molecular weight uraemic toxins molecules may have a negative effect on the cardiovascular and nutritional state of dialysis patients and influence uraemic symptomatology. Their clearance can be enhanced by the use of haemofiltration (HF). METHODS The effects of low-flux haemodialysis (HD) (ultrapure dialysate; polyamide membranes) and pre-dilution on-line HF (1:1 blood/substitution ratio; target filtration volume: 1.2 times body weight) on cardiovascular and nutritional parameters, interdialytic levels of uraemic toxins and quality of life (QOL; Laupacis questionnaire) were assessed during 1 year follow-up. Forty patients were randomized. RESULTS After 1 year, 27 patients were eligible for analysis (HF: 13 patients; HD: 14 patients). Left ventricular mass index did not change in the HF patients (127+/-33 --> 131+/-36 g/m(2) after 12 months) or in the HD group (135+/-34 --> 138+/-32 g/m(2)). Also, there were no changes in pulse wave velocity, and 48 h systolic and diastolic blood pressures. Lean body mass, assessed by dual-energy X-ray absorptiometry, increased in the HF group (44.8+/-8.9 --> 46.2+/-9.6 kg; P<0.05), but not in the HD group (49.4+/-9.2 --> 50.6+/-8.8 kg), although differences between groups were not significant. Insulin-like growth factor-1 levels remained stable in the HF patients, but decreased in the HD group (P<0.05 between groups). QOL for physical symptoms improved in the HF group (4.2+/-1.2 --> 5.0+/-1.1; P<0.05 within the HF group and P = 0.06 between groups), but not in the HD group (4.0+/-1.0 --> 4.4+/-1.4). beta2-microglobulin, complement factor D and homocysteine decreased significantly in the HF but not in the HD group, whereas l-ADMA, leptin and advanced glycation end-products-related fluorescence did not change. CONCLUSIONS No changes in cardiovascular parameters were observed during pre-dilution on-line HF compared with low-flux HD. Treatment with on-line HF resulted in marked changes in the uraemic toxicity profile, an improvement in physical well-being and a small improvement in nutritional state.
Collapse
Affiliation(s)
- Charles H Beerenhout
- Department of Nephrology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
135
|
Abstract
PURPOSE OF REVIEW Hypertension is highly prevalent in dialysis patients and may be important to the high cardiovascular mortality of this population. This review shows the current direction in dialysis-associated hypertension management. RECENT FINDINGS Decreasing dialysate sodium concentration based on pre-hemodialysis plasma sodium concentration may have an additive effect in controlling hypertension. Sympathetic nervous system overactivity is an important feature of end-stage renal disease; a new amine oxidase, renalase, may be relevant to the pathogenesis of hypertension in this population. Similarly, drugs that block the sympathetic nervous system are uniformly protective in dialysis patients. Daily dialysis (short or long) results in better blood pressure control, and the mechanisms resulting in this effect are increasingly better understood. SUMMARY Long-term control of hypertension is necessary in dialysis patients. The better understanding of the dialysis-associated hypertension pathogenesis has impact on the dialysis prescription and antihypertensive drug choices.
Collapse
Affiliation(s)
- Sergio F F Santos
- Division of Nephrology, State University of Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil
| | | |
Collapse
|
136
|
Konings CJ, Kooman JP, Gladziwa U, van der Sande FM, Leunissen KM. A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration. Kidney Int 2005; 67:1190-1. [PMID: 15698462 DOI: 10.1111/j.1523-1755.2005.191_2.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
137
|
Wiggins KJ, Rumpsfeld M, Blizzard S, Johnson DW. Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure. Nephrology (Carlton) 2005; 10:33-6. [PMID: 15705179 DOI: 10.1111/j.1440-1797.2005.00361.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND AND AIMS Icodextrin is a starch-derived glucose polymer that causes sustained ultrafiltration in long dwells in peritoneal dialysis. The aim of this study was to assess factors that were predictive of an increment in ultrafiltration following the introduction of icodextrin in patients with refractory fluid overload. METHODS Thirty-nine patients (20 male/19 female, mean age 57.7 +/- 2.4 years) on peritoneal dialysis were enrolled in a prospective pretest/post-test, open-label study. All patients had symptomatic fluid overload refractory to fluid restriction (<800 mL/day), frusemide doses of 250 mg or more daily, optimization of dwell time and use of hypertonic dextrose. An icodextrin exchange was substituted for a 4.25% dextrose exchange for the long-dwell period. RESULTS After 1 month, median (interquartile range) 24 h ultrafiltration volume increased by 500 mL (interquartile range: 50-1000). An increase in ultrafiltration volume correlated positively with the dialyate : plasma creatinine ratio at 4 h (r = 0.498, P = 0.001) and negatively with the ratio of dialysate glucose concentrations at 4 and 0 h (r = -0.464, P = 0.003). On multivariate regression analysis, high transporter status was predictive of a greater ultrafiltration response to icodextrin relative to dextrose peritoneal dialysis exchanges. Age, sex, race, peritoneal dialysis duration, peritoneal dialysis modality, diabetes mellitus, baseline albumin, and baseline ultrafiltration volume were not significantly correlated with the change in ultrafiltration volume. CONCLUSION Icodextrin significantly augments ultrafiltration volumes in patients with refractory fluid overload. A high peritoneal membrane transporter status is the best predictor of a favourable ultrafiltration response to icodextrin.
Collapse
Affiliation(s)
- Kathryn J Wiggins
- Department of Renal Medicine, University of Queensland at Princess Alexandra Hospital, Woolloongabba, Brisbane 4102, Queensland, Australia
| | | | | | | |
Collapse
|
138
|
Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2004; 16:546-54. [PMID: 15625070 DOI: 10.1681/asn.2004090793] [Citation(s) in RCA: 111] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Several clinical observations suggest the superiority of icodextrin compared with 4.25% dextrose in optimizing peritoneal ultrafiltration (UF), but no rigorous controlled evaluation has hitherto been performed. For comparing icodextrin and 4.25% dextrose during the long dwell of automated peritoneal dialysis, a multicenter, randomized, double-blind trial was conducted in 92 patients (control, 45; icodextrin, 47) with 4-h dialysate to plasma ratio creatinine >0.70 and D/D(0) glucose <0.34. Long-dwell net UF and the UF efficiency ratio (net UF volume per gram of dialysate carbohydrate absorbed) were determined at baseline, week 1, and week 2. The control and treatment groups were comparable at baseline (all patients using 4.25% dextrose for the long dwell) with regard to mean (+/-SEM) net UF (201.7 +/- 103.1 versus 141.6 +/- 75.4 ml, respectively; P = 0.637) and the percentage of patients with negative net UF (control, 37.8%; treatment, 42.6%; P = 0.641). During the study period, net UF was unchanged from baseline in the control group but increased significantly (P < 0.001) in the icodextrin group from 141.6 +/- 75.4 to 505.8 +/- 46.8 ml at week 1 and 540.2 +/- 46.8 ml at week 2. In the icodextrin group, the incidence of negative net UF was significantly lower (P < 0.0001) than in the control group. Findings were similar for UF efficiency ratio. Rash was reported significantly more often in the icodextrin group. This study showed that in high-average and high transporters, icodextrin is superior to 4.25% dextrose for long-dwell fluid and solute removal.
Collapse
|
139
|
Rodriguez-Carmona A, Pérez-Fontán M, Garca-Naveiro R, Villaverde P, Peteiro J. Compared time profiles of ultrafiltration, sodium removal, and renal function in incident CAPD and automated peritoneal dialysis patients. Am J Kidney Dis 2004; 44:132-45. [PMID: 15211446 DOI: 10.1053/j.ajkd.2004.03.035] [Citation(s) in RCA: 94] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND Fluid and sodium removal rates may not be equivalent in patients undergoing automated peritoneal dialysis (APD) and continuous ambulatory peritoneal dialysis (CAPD). This may influence compared cardiovascular outcomes in both groups. METHODS The authors compared prospectively the time courses of ultrafiltration, sodium removal, and residual renal function (RRF) in a group of incident patients treated with CAPD (n = 53) or APD (n = 51) for at least 1 year (mean follow-up, 28.9 months; range, 13 to 62). The authors analyzed potential effects of these factors on blood pressure (BP) control and cardiovascular morbidity and mortality. RESULTS Ultrafiltration and sodium removal rates were consistently lower in APD patients (mean differences, 236 mL/d; P = 0.012, and 36 mmol/d; P = 0.018, respectively, end of first year). Moreover, univariate and multivariate analysis indicated that APD therapy results in a moderate, but significantly faster decline of RRF than CAPD therapy. Analysis of clinical outcomes showed that CAPD (versus APD) therapy or higher ultrafiltration or sodium removal rates were associated with a better time course of systolic, but not diastolic, BP. We were unable to identify PD modality, ultrafiltration, or sodium removal rates as independent predictors of cardiovascular morbidity and mortality. CONCLUSION Ultrafiltration and sodium removal rates are consistently lower in incident APD patients than in their counterparts undergoing CAPD. Moreover, RRF declines faster during APD than during CAPD therapy, although this difference may be partially counteracted by a detrimental effect of ultrafiltration on RRF. Aside from a better control of systolic BP in CAPD patients, these differences do not portend significant cardiovascular consequences during the first years of PD therapy.
Collapse
|
140
|
Goffin E, Cosyns JP, Pirson F, Devuyst O. Icodextrin-associated peritonitis: what conclusions thus far? Nephrol Dial Transplant 2004; 18:2482-5. [PMID: 14605268 DOI: 10.1093/ndt/gfg368] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Eric Goffin
- Division of Nephrology, Université Catholique de Louvain Medical School, 10 Avenue Hippocrate, B-1200 Brussels, Belgium.
| | | | | | | |
Collapse
|
141
|
Abstract
UNLABELLED Icodextrin (Extraneal) is a high molecular weight glucose polymer developed specifically for use as an alternative osmotic agent to dextrose during the once-daily long-dwell exchange in peritoneal dialysis (PD). Isosmotic 7.5% icodextrin solution induces transcapillary ultrafiltration (UF) by a mechanism resembling 'colloid' osmosis (unlike hyper-osmolar dextrose-based solutions, which induce UF by crystalline osmosis). In addition, absorption of icodextrin from the peritoneal cavity is relatively slow compared with that of dextrose; this results not only in UF of longer duration, but also a lower carbohydrate load compared with medium (2.5%) and strong (4.25%) dextrose exchanges. In randomised clinical trials of up to 2 years in duration, administration of icodextrin for the long (8- to 16-hour) overnight exchange in continuous ambulatory peritoneal dialysis (CAPD) or daytime exchange in automated peritoneal dialysis (APD) produced net UF which exceeded that with 1.5% and 2.5% dextrose solutions (thereby improving fluid balance), and was equivalent to that with 4.25% dextrose solution. Icodextrin also increased peritoneal clearances of creatinine and urea nitrogen compared with 2.5% dextrose solution. The increase in UF volume with icodextrin was enhanced in CAPD patients with high peritoneal membrane permeability (i.e. high and high-average transporters), maintained in the small number of patients followed-up for 2 years and sustained during episodes of peritonitis. Icodextrin reduced the percentage of patients with net negative UF in contrast to 1.5% and 2.5% dextrose and, in noncomparative studies, extended PD technique survival in patients who had failed dextrose-based dialysis. The use of icodextrin was also associated with some symptomatic improvements and health-related quality of life advantages, and no adverse effect on patient survival, compared with dextrose, although confirmation of these findings is ideally required in appropriately designed studies. The tolerability of icodextrin was generally similar to that of dextrose-based solutions in controlled clinical trials, although there was an approximate three-fold increase in the risk of new skin rash (5.5% vs 1.7%). However, reports of severe cutaneous hypersensitivity reactions remain rare; this possibility should not preclude the use of the polymer. CONCLUSION 7.5% icodextrin solution offers the first feasible alternative to conventional dextrose solutions for the once-daily long-dwell exchange in PD. It is effective, generally well tolerated and appears to be most useful in situations of reduced or inadequate UF with dextrose, including in high and high-average transporters, during episodes of peritonitis and patients who have failed dextrose-based dialysis.
Collapse
Affiliation(s)
- James E Frampton
- Adis International Limited, Mairangi Bay, Auckland, New Zealand.
| | | |
Collapse
|
142
|
Charra B, Jean G, Chazot C, Hurot JM, Terrat JC, Vanel T, Lorriaux C, Vovan C. Intensive dialysis and blood pressure control: A review. Hemodial Int 2004; 8:51-60. [DOI: 10.1111/j.1492-7535.2004.00075.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
143
|
Affiliation(s)
- Anand Vardhan
- Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, Manchester, United Kingdom
| | | | | | | |
Collapse
|
144
|
McCormick BB, Bargman JM. The implications of the ADEMEX study for the peritoneal dialysis prescription: the role of small solute clearance versus salt and water removal. Curr Opin Nephrol Hypertens 2003; 12:581-5. [PMID: 14564193 DOI: 10.1097/00041552-200311000-00002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE OF REVIEW This review examines the results of the ADEMEX (Adequacy of Peritoneal Dialysis in Mexico) study in the context of other recent advances in peritoneal dialysis, and assesses the implication of this new knowledge for the optimal peritoneal dialysis prescription. RECENT FINDINGS The prospective randomized controlled ADEMEX study demonstrated no survival advantage of an increased dose of peritoneal small molecule clearance delivered by chronic ambulatory peritoneal dialysis. Coincident with this finding, there has been increasing awareness that many peritoneal dialysis patients are volume expanded, and that there are adverse cardiovascular consequences to this chronic overhydration. As a result there has been a shift away from interest in peritoneal small solute clearance with renewed interest in peritoneal removal of salt and water. There is also increasing evidence of the importance of residual renal function in maintaining euvolemia and as a prognostic indicator for survival. SUMMARY The ADEMEX study and subsequent investigations have changed the way we perceive the optimal peritoneal dialysis prescription. This has resulted in de-emphasis of peritoneal small molecule clearance and increased emphasis on clinical assessment of dialysis adequacy, preservation of residual renal function, and optimization of salt and water removal.
Collapse
|